MDS Nordion to partner with Avid Radiopharmaceuticals

AuntMinnie.com staff writers

Apr 3, 2007

Radioisotope developer MDS Nordion of Kanata, Ontario, will collaborate with Avid Radiopharmaceuticals to support clinical studies for the Philadelphia company's radiopharmaceuticals designed to diagnose and monitor Alzheimer's disease.

MDS Nordion will radiolabel Avid's proprietary compounds for use in proof-of-concept clinical trials for SPECT imaging of Alzheimer's disease.

By AuntMinnie.com staff writers
April 4, 2007

Related Reading

MDS Nordion to expand Belgian FDG facility, March 22, 2007

MDS names Prince as CFO, February 20, 2007

MDS Nordion opens European TheraSphere centers, February 8, 2007

MDS Nordion shows Q4 revenue downturn, year-end upturn, December 14, 2006

MDS sells diagnostics unit, October 5, 2006

Copyright © 2007 AuntMinnie.com

Pet Amygdala Thumbnail

PET links chronic stress to aggressive endometrial cancer

November 19, 2024

New! Imaging Life Issue 20 now available

New! Imaging Life Issue 20 now available

November 5, 2024

Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.

New PET tracer shows promise in patients with kidney cancer

November 14, 2024

Pluvicto Spect Ct Response Thumbnail

SPECT/CT predicts treatment response in Pluvicto patients

November 1, 2024

PET links chronic stress to aggressive endometrial cancer

Brain activity related to chronic stress may be associated with the aggressiveness of tumors in women with endometrial cancer.

November 19, 2024

Pet Amygdala Thumbnail

FAPI-PET/CT superior to FDG-PET/CT in assessing liver cancer

A recent study suggests that PET/CT imaging with a FAPI radiotracer is superior to F-18 FDG-PET/CT for assessing patients with liver cancer.

November 18, 2024

Two cases of pathologically confirmed intrahepatic cholangiocarcinomas in 68-year-old male patients. In both cases (A-H, case 1; I-P, case 2), CT scans (B, F, case 1; J, N, case 2) revealed intrahepatic bile duct dilation and suspected nodular lesions. While F-18 FDG PET/CT (A, C, D, case 1; I, K, L, case 2) failed to demonstrate abnormal tracer uptake (SUVmax 3.5, TBR 1.3 in Case 1; SUVmax 2.6, TBR 1.2 in Case 2), F-18 FAPI-04 PET/CT (E, G, H, case 1; M, O, P, case 2 ) showed positive uptake in the nodular lesions (SUVmax 9.7, TBR 3.5 in Case 1; SUVmax 9.6, TBR 3.3 in Case 2). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of BMC Cancer.

New PET tracer shows promise in patients with kidney cancer

A new PET radiotracer could offer a viable strategy for detecting primary tumors, involved lymph nodes, and distant metastases in patients with clear cell renal cell carcinoma.

November 14, 2024

Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.

SPECT/CT predicts treatment response in Pluvicto patients

SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.

November 1, 2024

Pluvicto Spect Ct Response Thumbnail

FCH-PET emerging in patients with hyperparathyroidism

F-18 fluorocholine (FCH) PET/CT appears to be an effective first-line imaging method in patients with primary hyperparathyroidism.

October 31, 2024

Hyperparathyroidism

Ask cardiac PET patients how much they exercise, study suggests

Exercise activity is an independent predictor of events such as heart attacks in patients undergoing stress PET myocardial perfusion imaging.

October 30, 2024

Intraarterial PRRT safe in patients with meningioma

Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.

October 28, 2024

2024 10 28 Meningioma Thumbnail

PSMA-PET provides long-term benefits

Prostate-specific membrane antigen (PSMA) PET imaging could improve the length and quality of life for patients with recurrent prostate cancer.

October 24, 2024

Prostate Imaging2

New PET tracer improves detection of insulinomas

A new PET/CT radiotracer that detects insulinomas could eliminate the need for other diagnostic procedures in a vast majority of patients.

October 21, 2024

Glp 1 R Pet 67169a712e569 Thumbnail

Tc-99m shortage expected into November

The delayed restart of a nuclear research reactor in the Netherlands is expected to cause supply shortages of technetium-99m (Tc-99m) into November.

October 18, 2024

FAPI-PET shows value in staging lung cancer patients

Fibroblast activation protein inhibitor (FAPI) PET/CT shows excellent diagnostic accuracy for detecting lymph node metastases in lung cancer patients

October 17, 2024

New guidelines cover theranostics for brain tumors

The use of somatostatin receptor PET imaging and therapy in meningiomas is on the rise.

October 14, 2024

Page 1 of 598